Aspirin shows inferior efficacy in curbing blood clot risk in myeloma

09/11/2013 | MyelomaBeacon.com

A French study in the journal Thrombosis and Haemostasis found that aspirin was inferior to vitamin K antagonists and low-molecular weight heparin in preventing blood clots in myeloma patients taking Revlimid or thalidomide. The results suggest that clinicians prescribe low-molecular weight heparin or vitamin K antagonists to high-risk patients and that treatment should be continued as needed to address clotting risk, researchers said.

View Full Article in:

MyelomaBeacon.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health